title: Exogenous lysozyme influences Clostridium perfringens colonization and intestinal barrier function in broiler chickens.
abstract: Necrotic enteritis is a worldwide poultry disease caused by the overgrowth of Clostridium perfringens in the small intestine. An experiment with a 2x2 factorial design (supplementation with or without 40 mg lysozyme/kg diet for chickens challenged with or without C. perfringens) was conducted to investigate the inhibitory efficacy of exogenous lysozyme against intestinal colonization by C. perfringens in chickens subject to oral inoculation of C. perfringens type A on days 17 to 20. The C. perfringens challenge resulted in significant increase of C. perfringens, Escherichia coli and Lactobacillus populations in the ileum, bacteria translocation to the spleen, the intestinal lesion scores , There was significantly lower intestinal lysozyme activity in the duodenum and jejunum and weight gain during days 14 to 28 of the experiment. The addition of exogenous lysozyme significantly reduced the concentration of C. perfringens in the ileum and the intestinal lesion scores, inhibited the overgrowth of E. coli and Lactobacillus in the ileum and intestinal bacteria translocation to the spleen, and improved intestinal lysozyme activity in the duodenum and the feed conversion ratio of chickens. These findings suggest that exogenous lysozyme could decrease C. perfringens colonization and improve intestinal barrier function and growth performance of chickens.
authors.affiliation: The State Key Lab of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Liu
authors.forename: Yuming
authors.initials: Y
authors.lastname: Guo
authors.forename: Zhong
authors.initials: Z
authors.lastname: Wang
authors.forename: Jianmin
authors.initials: J
authors.lastname: Yuan
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000378:metabolism; D002645:Chickens; D003015:Clostridium Infections / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology / Q000473:pathology / Q000662:veterinary*; D003016:Clostridium perfringens / Q000187:drug effects* / Q000254:growth & development; D019587:Dietary Supplements; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects / Q000382:microbiology / Q000473:pathology; D007778:Lactobacillus / Q000187:drug effects / Q000254:growth & development; D009113:Muramidase / Q000008:administration & dosage* / Q000378:metabolism; D011201:Poultry Diseases / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology* / Q000473:pathology; D013154:Spleen / Q000382:microbiology; D015430:Weight Gain / Q000187:drug effects
chemical_list: D000890:Anti-Infective Agents; D009113:Muramidase